1. Evaluation of the cassette dosing approach for assessing the pharmacokinetics of geldanamycin analogues in mice

   • N. F. Smith
   • A. Hayes
   • P. Workman

   Original Article 29 July 2004 Pages: 475 - 486

   

2. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors

   • Laura L. Jung
   • Ramesh K. Ramanathan
   • William C. Zamboni

   Original Article 18 August 2004 Pages: 487 - 496

   

3. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFβ-RII, KRAS2, TP53 and/or CDNK2A

   • V. Samouëlian
   • C. M. Maugard
   • A.-M. Mes-Masson

   Original Article 16 July 2004 Pages: 497 - 504

   

4. Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro

   • Yasuhiko Kano
   • Miyuki Akutsu
   • Yusuke Furukawa

   Original Article 31 August 2004 Pages: 505 - 513

   

5. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study

   • Klaus Mross
   • Bernward Niemann
   • Christine E. Swenson

   Original Article 21 August 2004 Pages: 514 - 524

   

6. Inhibition of P-glycoprotein activity and reversal of cancer multidrug resistance by Momordica charantia extract

   • Pornngarm Limtrakul
   • Orawan Khantamat
   • Komsak Pintha

   Original Article 10 July 2004 Pages: 525 - 530

   

7. Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer

   • Takashi Tsuji
   • Terumitsu Sawai
   • Yutaka Tagawa

   Original Article 10 August 2004 Pages: 531 - 536

   

8. Synergistic killing of human leukemia cells by antioxidants and trichostatin A

   • Jiuhong Kang
   • Jie Chen
   • Yingxian Ou

   Original Article 10 July 2004 Pages: 537 - 545

   

9. Docetaxel and high-dose epirubicin as neoadjuvant chemotherapy in locally advanced breast cancer

   • E. Espinosa
   • S. Morales
   • M. González Barón

   Original Article 17 August 2004 Pages: 546 - 552

   

10. A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases

    • Olatoyosi M. Odenike
    • Ronald M. Sobecks
    • Richard A. Larson

    Original Article 02 September 2004 Pages: 553 - 561

11. A 150-kDa glycoprotein isolated from Solanum nigrum L. has cytotoxic and apoptotic effects by inhibiting the effects of protein kinase C alpha, nuclear factor-kappa B and inducible nitric oxide in HCT-116 cells

    • Sei-Jung Lee
    • Phil-Sun Oh
    • Kye-Taek Lim

    Original Article 02 September 2004 Pages: 562 - 572

    

12. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer

    • Minoru Fukuda
    • Mikio Oka
    • The Nagasaki Thoracic Oncology Group

    Original Article 10 September 2004 Pages: 573 - 577